A retrospective study on screening and management of osteoporosis in breast cancer women treated with aromatase inhibitors in Libya.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  CLINICAL CASES IN MINERAL AND BONE METABOLISM

• Publication date

  2016-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.11138/ccmbm/2016.13.3.186PMID 28228779PMCID PMC5318169
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2015influential reference
• NCCN Task Force Report: Bone Health In Cancer Care.

  2013cited by this paper
• Osteoporosis and aromatase inhibitors: experience and future prospects.

  2012cited by this paper
• American society of clinical oncology clinical practice guideline update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.

  2010cited by this paper
• Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial

  2010cited by this paper
• Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial.

  2010cited by this paper
• Impact of aromatase inhibitors on bone health in breast cancer patients.

  2010cited by this paper
• Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2010cited by this paper
• A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer

  2010cited by this paper
• American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.

  2010cited by this paper
• Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC

  2009cited by this paper
• The effect of aromatase inhibitors on bone metabolism.

  2009cited by this paper
• Hormonal deprivation therapy-induced osteoporosis in postmenopausal women with breast cancer.

  2009cited by this paper
• Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results.

  2009cited by this paper
• Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer.

  2008cited by this paper
• Effective inhibition of aromatase inhibitor‐associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole

  2008cited by this paper
• Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial.

  2008cited by this paper
• Practical guidance for the management of aromatase inhibitor-associated bone loss.

  2008cited by this paper
• Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.

  2008cited by this paper
• The effect of tamoxifen or exemestane on bone mineral density during the first 2 years of adjuvant treatment of postmenopausal women with early breast cancer.

  2008cited by this paper
• Effect of Tamoxifen and Aromatase Inhibitors on the Risk of Fractures in Women with Breast Cancer

  2008cited by this paper
• Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007.

  2007cited by this paper
• [Effect of aromatase inhibitors on bone metabolism].

  2007cited by this paper
• NCCN Task Force Report: Bone Health in Cancer Care.

  2006cited by this paper
• Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group.

  1994cited by this paper
• Book review: Assessment of fracture risk and its application to screening for postmenopausal osteoporosis.

  1994cited by this paper

• No citing papers are available for this paper.